We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02438007
Recruitment Status : Terminated
First Posted : May 8, 2015
Last Update Posted : September 28, 2017
Information provided by (Responsible Party):
Novus Therapeutics, Inc

Brief Summary:
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Galeterone Drug: Enzalutamide Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 953 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)
Study Start Date : June 2015
Primary Completion Date : July 2016
Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Galeterone Drug: Galeterone
2550 mg galeterone tablets once daily PO
Other Name: TOK-001
Active Comparator: Enzalutamide Drug: Enzalutamide
160 mg enzalutamide capsules once daily PO
Other Name: Xtandi®

Primary Outcome Measures :
  1. Radiographic Progression-free survival [ Time Frame: ≥ 8 months ]

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: ≥ 8 months ]
  2. Time to Initiation of Cytotoxic Chemotherapy [ Time Frame: ≥ 8 months ]

Other Outcome Measures:
  1. Skeletal-related Events [ Time Frame: ≥ 8 months ]
  2. Safety measured by clinical safety laboratories and adverse events [ Time Frame: ≥ 8 months ]
  3. Prostate Specific Antigen (PSA) Response ≥ 50% [ Time Frame: ≥ 8 months ]
  4. Time to PSA progression [ Time Frame: ≥ 8 months ]
  5. Time to ECOG deterioration [ Time Frame: ≥ 8 months ]
  6. Best Overall Response by RECIST 1.1 [ Time Frame: ≥ 8 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Progressive metastatic (M1) disease on androgen deprivation therapy
  • Detectable AR-V7 from circulating tumors (CTCs)
  • ECOG performance status 0 or 1

Exclusion Criteria:

  • Prior treatment with second generation anti-androgens (e.g. abiraterone, enzalutamide)
  • Prior treatment with chemotherapy for CRPC

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02438007

  Show 117 Study Locations
Sponsors and Collaborators
Novus Therapeutics, Inc

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novus Therapeutics, Inc
ClinicalTrials.gov Identifier: NCT02438007     History of Changes
Other Study ID Numbers: ARMOR3-SV
First Posted: May 8, 2015    Key Record Dates
Last Update Posted: September 28, 2017
Last Verified: September 2017

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs